Nebu~Flow

Primary contact
11 The Square
University Avenue
G12 8QQ Glasgow
Scotland
United Kingdom
11 The Square
University Avenue
G12 8QQ Glasgow
Scotland
United Kingdom
Links
https://nebuflow.com/
https://nebuflow.com/
Sections Medical Devices
Funding π°
Total Β£2.7M
Select investors Foresight Williams, Ascension, Science Creates Ventures, SIS Ventures, Innovate UK
Key people π§βπ€βπ§
- Elijah Nazarzadeh - CEO
- John Pritchard - Chairman
- Steven Beaumont - Director
- Jon Cooper - Director
- Harry Destecroix - Director
- Bill Yost - Director
Highlights β
- Patented tech: Nebu~Flow is developing its nebuliser platform that enables efficient delivery of a wide range of formulations. It features a short nebulisation time, it's easy to clean, silent, while supporting a wide range of formulations.
- It works: Nebu~Flow uses surface acoustic wave (SAW) nebulisation technology and has been used successfully to nebulise a range of placebo and commercially available formulation types with a wide range of physical properties, including those with very low surface tension and high viscosity. π
- Big market: Global nebuliser market is valued at more than $1 billion, while the worldwide inhalable drug market is estimated to be worth more than $43 billion in 2022. π
Awards & Recognitions π
- 2020 Lee Lucas Award
- 2019 Scottish Edge HIGGS: Winner
Quotes π¬
“
Nebu~Flow's development of delivery mechanisms tailored to specific drugs represents an opportunity to expand the market and improve patient outcomes. Foresight Williams Technology's expertise will offer significant value as the company develops its products, and we look forward to working with the team at Nebu-Flow during the next stage of their growth.
— Bill Yost, investment manager at Foresight π
Last update: April 5, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more